# NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

> **NCT05290493** · PHASE2 · COMPLETED · sponsor: **Nobias Therapeutics, Inc.** · enrollment: 37 (actual)

## Conditions studied

- 22q11 Deletion Syndrome

## Interventions

- **DRUG:** NB-001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05290493
- **Lead sponsor:** Nobias Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-10
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05290493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05290493, "NB-001 in Children and Adolescents With 22q11 Deletion Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05290493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*